Develops therapeutics for unmet medical needs using its proprietary TransCon technology. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 207% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 207% a year on average.
The company sells $802.6M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 14 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $254.1M against $802.6M in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 37/100.
On our five-subject report card, ASND sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ASND has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (37/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.